Key result
Topical apraclonidine lowers intraocular pressure comparably to timolol without affecting blood pressure or heart rate.
Why the study?
Does topical apraclonidine affect cardiovascular parameters and intraocular pressure compared to timolol and placebo in healthy female volunteers?
RCT (n=20)
Double-blind
Does topical apraclonidine affect cardiovascular parameters and intraocular pressure compared to timolol and placebo in healthy female volunteers?
Topical apraclonidine lowers intraocular pressure without the systemic cardiovascular effects (such as blunting exercise-induced tachycardia) associated with timolol.
Authors
No takes yet. Share an insight, caveat, or question.
Apraclonidine matches timolol for IOP reduction without blunting exercise tachycardia; supports use in patients at cardiovascular risk and extends alpha-agonist options.
Anne L. Coleman (1990) conducted an RCT in Healthy volunteers (n=20). Topical apraclonidine hydrochloride vs. 0.5% timolol maleate and placebo was evaluated on Intraocular pressure and cardiovascular effects. Topical apraclonidine (0.5% and 0.25%) lowered intraocular pressure comparably to 0.5% timolol, without affecting blood pressure or heart rate differently than placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: